Joseph W. Leach

TL;DR: Overall survival was significantly longer with atezolizumab in the ITT and PD-L1-expression populations, and overall survival improvement was similar in patients with squamous non-squamous lung cancer.

TL;DR: 1 year of extended adjuvant therapy with neratinib, administered after chemotherapy and trastuzumab, significantly reduced the proportion of clinically relevant breast cancer relapses-ie, those that might lead to death, such as distant and locoregional relapses outside the preserved breast-without increasing the risk of long-term toxicity.

TL;DR: The addition of veliparib to frontline chemotherapy showed signal of efficacy in patients with ES-SCLC and the study met its prespecified end point.

TL;DR: Long-term n-BIS therapy and recent dental procedures are consistent findings in patients withBRONJ, and spontaneous BRONJ lesions respond favorably to current BRonJ treatment strategies.

TL;DR: Increased cumulative doses and long-term BP treatment are the most important risk factors for BRONJ development.